ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Plans Preclinical Studies Of Endoxifen, A Tamoxifen Metabolite.

August 7, 2009

Guest Editorial “Gizmo Idolatry” and Marketing Da Vinci’s Radical Robot

September 26, 2014

Funding Opportunities: CDC Seeks Initiatives For Tobacco Control; NCI RFA Available

May 8, 1998

EARLY Breast Cancer Screening Bill Gains Traction Among Jewish Groups

June 19, 2009

NCI To Commit $10 Million For SBIR Phase II Bridge Awards.

June 20, 2008

Former NCAB chairman, President’s Cancer Panel member Paul Calabresi dead at 73.

October 31, 2003